Sourcery• Aug 22, 2025• 57:46Interview

How 8VC Builds Billion-Dollar Companies | Palantir, Addepar, Saronic

From Sourcery

Drew Oding

Executive Summary

Venture capital firm 8VC dedicates 30% of its capital and resources to its '8VC Build' program, a differentiated strategy focused on co-founding companies to tackle complex challenges in industrial and governmental sectors.
The re-industrialization of the United States is a central theme, requiring a new level of collaboration between startups and the federal government to overcome high costs, labor shortages, and regulatory hurdles.
Key sectors driving this movement include defense tech (Anduril, Saronic), biotech manufacturing (Resilience), and construction automation (Bedrock Robotics), which are attracting significant venture investment.
The speaker is highly bullish on the long-term potential of genomic medicines, predicting an economic impact comparable to AI, but acknowledges that negative market sentiment and high capital costs are significant near-term headwinds for the biotech industry.

12 quotes

Concerns Raised

High costs, labor shortages, and regulatory hurdles are significant barriers to US re-industrialization.
A capital gap exists for growth-stage industrial companies that require project financing, which venture capital doesn't typically provide.
Negative market sentiment and the tendency for biotech companies to IPO prematurely are harming innovation in the life sciences sector.
The rising US national debt may constrain future government investment and industrial policy.
Environmental regulations in the US make domestic pharmaceutical chemical production significantly more expensive than in other countries.

Opportunities Identified

Co-founding companies via a dedicated 'Build' program allows for tackling complex, capital-intensive problems in critical sectors.
The immense long-term potential of genomic medicines, with an expected economic impact nearly as large as AI.
Automating the construction industry to address severe labor shortages and high costs.
Leveraging the experienced talent pools from Palantir and SpaceX to build the next generation of defense technology companies.
Increased government focus and funding for onshoring critical manufacturing, particularly in defense and pharmaceuticals.

Key Themes

Venture Capital as Company Builder

The discussion details 8VC's unique model of co-founding companies through its formalized '8VC Build' program, which allocates 30% of the firm's resources. This hands-on approach, which includes an active EIR program, is positioned as a more effective way to build businesses in complex, capital-intensive sectors compared to traditional venture investing.

This model represents a differentiated strategy in venture capital, designed to de-risk and accelerate companies tackling fundamental industrial, defense, and healthcare problems that require deep operational involvement from the start.

The American Re-industrialization Movement

A core focus is the strategic push to rebuild America's domestic manufacturing and industrial base, driven by geopolitical tensions and supply chain vulnerabilities exposed by the pandemic. This effort involves significant investment in 'hard tech' sectors like defense, pharmaceuticals, and construction.

This trend signals a major shift in economic policy and private investment, creating opportunities for startups that can enhance national security, onshore critical production, and modernize legacy industries.

Public-Private Partnership in Critical Industries

The successful revitalization of US industry is predicated on unprecedented collaboration between innovative startups and the federal government. The conversation highlights how companies in defense tech and biotech must navigate government bureaucracy and align with national priorities to succeed.

For founders and investors in these domains, understanding and fostering relationships with government entities is no longer optional but a core competency for go-to-market strategy, securing contracts, and influencing policy.

Challenges in US Biotech and Pharma Manufacturing

The episode explores the strategic imperative to onshore pharmaceutical manufacturing, exemplified by the founding of Resilience. It details the significant barriers, including high fixed costs, stringent environmental regulations, and risk-averse processes within large pharma companies, which stifle innovation.

This highlights a critical national security vulnerability and a market opportunity for new technologies and business models that can make domestic biotech manufacturing more cost-effective, efficient, and environmentally sustainable.

Capital and Labor Gaps in 'Hard Tech'

The conversation points to fundamental constraints hindering the re-industrialization effort: a massive labor shortage in industries like construction and a significant capital gap for growth-stage companies that need project or infrastructure financing beyond what typical venture capital provides.

These gaps represent major risks for industrial startups but also create opportunities for innovation in automation (e.g., Bedrock Robotics) and financial products tailored to the unique capital needs of building physical infrastructure.

Get started free

Topics

Re-industrialization Venture Capital Company Building 8VC Public-Private Partnership Defense Tech Biotech Pharmaceutical Manufacturing Genomic Medicine National Security Supply Chain Construction Tech Automation Capital Formation US Economy Anduril Resilience Palantir Government Contracting

Processed Apr 6, 2026 yt-dlp + mlx-whisper + Gemini